Price of Gilead’s Sovaldi expected at KRW 30 million in negotiation

The company seems to drop greediness. It was observed that Gilead will decide the price of ‘Sovaldi,’ a hepatitis C treatment approved domestically on the last 10^th, at a lower price than the ones in other countries.

What has been observed is approximately KRW 30 million(the price after completion of treatment). According to the academic society on the 14^th, Gilead Sciences Korea selected the ...